Could New Data Herald China Approval For Comirnaty?
Executive Summary
Long-term safety results from the mRNA COVID-19 vaccine’s Phase II trial in a Chinese population could pave the way for its approval in China, investigators say.
You may also be interested in...
China's mRNA Shot Shows Benefits Over Older COVID Vaccines
Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.
Facing COVID Surge, China Revises Course To Support Imported mRNA Vaccines
Latest announcement from Shanghai government set to open foreign mRNA jabs to the arms of Chinese people, after months of stalling approvals.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.